Getting a drug approved for commercial use is difficult. For biotech companies, that isn’t the full extent of the challenge.

This can be seen in fourth-quarter results of Keryx Biopharmaceuticals, which makes a phosphate binder used in treating chronic kidney disease. Its drug, Auryxia, generated great excitement. From the start of 2013 through the Food and Drug Administration’s approval of Auryxia on Sept. 5, 2014, Keryx returned...